Search

Displaying results 4971 - 4980 of 10000 in total
  1. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

    Synonyms: Sn Mesoporphyrin, Tin mesoporphyrin
  2. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.

  3. Drug

    Pranlukast

    go.drugbank.com/drugs/DB01411
    Investigational

    It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens. … Pranlukast is a cysteinyl leukotriene receptor-1 antagonist.

  4. Drug

    Isoxsuprine

    go.drugbank.com/drugs/DB08941
    ApprovedWithdrawn

    Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.

  5. Drug

    Thioredoxin

    go.drugbank.com/drugs/DB11298
    Approved

    Thioredoxin is a small dithiol protein and specific reductant for major allergenic proteins present in foods from animal and plant products. … It plays an essential role as an antioxidant in neutralizing food allergens and redox signalling. Allergens containing disulfide bonds are inactivated when reduced by thioredoxin.

  6. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    [A257296] It is being investigated in other cancers. … Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours.

  7. Drug

    TA-NIC

    go.drugbank.com/drugs/DB05445
    Investigational

    TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. … It is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain, to reduce the addictive

  8. Drug

    Hydroquinidine

    go.drugbank.com/drugs/DB15300
    Investigational

    Hydroquinidine is under investigation in clinical trial NCT00927732 (Hydroquinidine Versus Placebo in Patients With Brugada Syndrome).

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ia
  9. Drug

    Flucloxacillin

    go.drugbank.com/drugs/DB00301
    ApprovedInvestigationalWithdrawn

    Antibiotic analog of cloxacillin.

  10. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. … PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.